Peetz Christopher 4

What Happened

• Christopher Peetz, CEO of Mirum Pharmaceuticals, had 12,797 restricted stock units vest/convert into common shares on Jan 21, 2026 (reported as derivative conversion). To cover tax withholding tied to the vesting, 7,098 shares were sold in the open market on Jan 22, 2026 at $93.33 per share, generating $662,422. The net result of the vesting and sale is that Peetz retained 5,699 shares from this award.

Key Details

• Transaction dates and prices:
  • 2026-01-21: RSUs converted to 12,797 shares (conversion/exercise, no cash price).
  • 2026-01-22: Open-market sale of 7,098 shares at $93.33 each, proceeds $662,422.
• Shares retained after the transactions: 5,699 (12,797 vested minus 7,098 sold).
• Footnotes:
  • F1: Each RSU represents the right to one share of common stock.
  • F2: Shares were sold to cover tax withholding on the RSU vesting.
  • F3: The RSU award vests 1/3 each year starting Jan 21, 2025 (fully vested after three years).
• Filing: Form 4 was filed Jan 23, 2026 covering transactions on Jan 21–22, 2026; no late filing flag noted.

Context

• This was not a cash purchase; it was an RSU vesting event followed by a sale to satisfy tax withholding (a common, routine insider transaction). For retail investors, sales to cover taxes are generally administrative and do not necessarily indicate a change in the insider’s view of the company.